Lataa...
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
OBJECTIVE: To investigate the efficacy, safety and immunogenicity of PF-06438179/GP1111 (PF-SZ-IFX) compared with European reference infliximab (Remicade(®); ref-IFX) in patients with moderate-to-severe, active rheumatoid arthritis after continued long-term use of PF-SZ-IFX, and in patients who were...
Tallennettuna:
| Julkaisussa: | RMD Open |
|---|---|
| Päätekijät: | , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6446180/ https://ncbi.nlm.nih.gov/pubmed/30997153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2018-000876 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|